Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49


Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.

de la Fouchardière C, Négrier S, Labrosse H, Martel Lafay I, Desseigne F, Méeus P, Tavan D, Petit-Laurent F, Rivoire M, Pérol D, Carrie C.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):409-13. doi: 10.1016/j.ijrobp.2009.05.008. Epub 2010 Jan 29.


Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.

Takeda K, Negoro S, Kudoh S, Okishio K, Masuda N, Takada M, Tanaka M, Nakajima T, Tada T, Fukuoka M.

Br J Cancer. 1999 Mar;79(9-10):1462-7.


A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.

Tedesco KL, Berlin J, Rothenberg M, Choy H, Wyman K, Scott Pearson A, Daniel Beauchamp R, Merchant N, Lockhart AC, Shyr Y, Caillouette C, Chakravarthy B.

Radiother Oncol. 2005 Jul;76(1):54-8.


Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer.

Ashamalla H, Zaki B, Mokhtar B, Colella F, Selim H, Krishnamurthy M, Ross P.

Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):679-87. Erratum in: Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1158.


A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C, Cunningham D.

Ann Oncol. 2003 Aug;14(8):1264-9.


Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Nakagawa A, Kawakami H, Uno T, Ito H, Saisho H.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):219-24.


Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.

Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):974-81.


Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.

Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, Nakagohri T, Inoue K, Ogino T, Ikeda H, Maru Y, Yoshino M.

Cancer. 2003 Mar 1;97(5):1346-52.


Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ, George J.

J Clin Oncol. 2009 Sep 1;27(25):4089-95. doi: 10.1200/JCO.2008.20.8116. Epub 2009 Aug 3.


A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.

Childs HA 3rd, Spencer SA, Raben D, Bonner JA, Newsome J, Robert F.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):939-44.


Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.

Gridelli C, Guida C, Barletta E, Gatani T, Fiore F, Barzelloni ML, Rossi A, de Bellis M, D'Aniello R, Scognamiglio F.

Lung Cancer. 2000 Aug;29(2):131-7.


Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.

Tsujie M, Nakamori S, Tanaka E, Nagano H, Umeshita K, Dono K, Sakon M, Inoue T, Inoue T, Monden M.

Jpn J Clin Oncol. 2006 Aug;36(8):504-10. Epub 2006 Jul 19.


A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.

Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C.

Cancer Chemother Pharmacol. 2006 Aug;58(2):165-72. Epub 2005 Nov 19.


Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.

Glimelius B, Ristamäki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, Linné T, Frödin JE, Boussard B, Oulid-Aïssa D, Pyrhönen S.

Ann Oncol. 2002 Dec;13(12):1868-73.


Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB.

J Clin Oncol. 2001 Feb 15;19(4):1078-87.


Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.

J Clin Oncol. 1995 Jan;13(1):210-21.


Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.

Comella P, Casaretti R, De Vita F, Avallone A, Orditura M, Petrillo A, Gravina A, Faranda A, Comis S, Comella G, Catalano G.

Ann Oncol. 1999 Aug;10(8):915-21.


Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.

Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ, Wanebo H.

Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):53-7.

Items per page

Supplemental Content

Write to the Help Desk